Site selection is where clinical trials succeed or fail long before the first patient is ever screened. Sponsors and CROs pour enormous resources into feasibility assessments, yet a significant share of selected sites still underperform on enrollment, generate excessive protocol deviations, or fail quality audits. For research sites competing for study allocations, and for sponsors trying to build a reliable site network, understanding what actually predicts site performance, beyond what appears on a feasibility questionnaire, is critical.

What Feasibility Surveys Actually Measure (and What They Miss)

Standard feasibility surveys ask sites to self-report patient population size, prior study experience, staff certifications, equipment, and projected enrollment numbers. These are useful baseline filters, but they are also easy to overstate, and sponsors know it. Nearly every site reports an optimistic enrollment projection; the sites that actually hit those numbers are a much smaller subset.

What feasibility surveys frequently fail to capture:

  • Real screen-fail rates from comparable past studies, not just enrollment totals
  • Coordinator-to-patient ratio and actual staff bandwidth, not just headcount on paper
  • Whether the "patient population" claimed is an actual, accessible database or a theoretical catchment area
  • Historical protocol deviation and audit finding rates
  • Site startup timeline history: how long it actually took from contract execution to first patient in for prior studies

The Rise of Data-Driven Site Selection

Sponsors are increasingly supplementing feasibility surveys with claims data, electronic health record (EHR) analytics, and third-party site performance databases to validate what sites report. This shift has significant implications for how sites should position themselves in business development conversations: claims without supporting data are losing credibility, while sites that can produce concrete historical performance metrics are winning disproportionate allocation.

Embedded Health Networks as a Feasibility Advantage

Research sites embedded within larger healthcare systems, such as urgent care networks, primary care groups, or multi-specialty practices, have a structural advantage in feasibility conversations. Rather than relying on a single site's patient database, an embedded model can point to the aggregate patient population across dozens of clinics feeding into a smaller number of research sites. A network with six embedded research sites drawing from thirty or more clinics, for example, can credibly claim access to a patient population an order of magnitude larger than a standalone research site, while also demonstrating existing patient trust and provider relationships that don't need to be built from scratch.

The Site Qualification Visit: What Sponsors Are Really Evaluating

Beyond paperwork, the site qualification visit (SQV) remains one of the most predictive steps in the selection process. Sponsors and CRAs are assessing far more than regulatory binders and freezer temperatures during these visits. Key evaluation points that separate strong performers from marginal ones include:

Principal Investigator Engagement

A PI who is visibly engaged, asks substantive protocol questions, and has a track record of hands-on study oversight (rather than delegating everything to a sub-investigator) signals lower risk to sponsors. PIs juggling too many concurrent studies, or who show limited familiarity with the therapeutic area, are a common feasibility red flag.

Coordinator Experience and Retention

High coordinator turnover at a site is one of the strongest predictors of enrollment problems and data quality issues. Sponsors increasingly ask directly about staff tenure during SQVs, because a site that churns coordinators every twelve to eighteen months will consistently underperform sites with a stable, experienced team.

Regulatory and Quality Infrastructure

Sites need to demonstrate a functioning quality management system, not just a binder of SOPs. Sponsors are looking for evidence of internal audits, CAPA (corrective and preventive action) processes, and a track record of clean FDA or sponsor audits.

IT and Data Systems Readiness

With the growth of electronic data capture (EDC), eConsent, and remote monitoring, sites that lack modern, interoperable systems create friction that shows up in query resolution times and data lock delays. Sites investing in updated clinical trial management systems (CTMS) and EDC-compatible infrastructure are increasingly favored in feasibility scoring.

Business Development Strategy for Site Selection Success

For business development teams representing research sites, winning feasibility allocations in a competitive market requires a shift from generic capability pitches to evidence-based positioning. Practical strategies that consistently improve win rates:

  • Build a living metrics dashboard: enrollment velocity, screen-fail rate, retention rate, protocol deviation rate, and audit history, updated after every study and ready to share proactively.
  • Segment your pitch by therapeutic area: sponsors want to see relevant experience, not a generic "we can do anything" pitch. A site with three completed diabetes trials should lead with diabetes-specific enrollment data when responding to an endocrinology feasibility survey.
  • Respond to feasibility surveys fast and completely: sponsors and CROs are working through dozens of site responses under tight timelines. Sites with a templated, rapid-turnaround feasibility response process consistently get more allocations simply by being easier to work with.
  • Cultivate direct sponsor and CRO relationships outside of formal RFPs: warm introductions and existing relationships (through conferences, prior studies, or personal networks) remain one of the highest-converting channels for new study allocation, even in an increasingly data-driven selection environment.
  • Leverage confidentiality and master agreements: sites with executed CDAs, MCDAs, and master service agreements already in place with major sponsors and CROs reduce startup friction, which is itself a competitive advantage sponsors actively favor when timelines are tight.

Several shifts are reshaping how sites are selected and how sponsors build their site networks:

  • Site network consolidation: sponsors increasingly prefer working with multi-site networks and site management organizations (SMOs) over one-off single-site relationships, reducing the number of individual site relationships they need to manage per study.
  • Community and non-academic sites gaining share: with academic medical centers facing capacity constraints and slower startup timelines, community-based and urgent-care-embedded sites are capturing a growing share of study allocations, particularly for later-phase and real-world evidence studies.
  • Predictive feasibility analytics: more sponsors are using AI-driven tools to model expected enrollment based on historical site performance data rather than relying solely on self-reported projections.
  • Faster startup expectations: sponsors are compressing timelines industry-wide, putting a premium on sites that can demonstrate rapid IRB submission, contract turnaround, and first-patient-in timelines.

Practical Takeaways

Winning site allocations in today's market requires moving beyond the feasibility questionnaire and building a genuine, evidence-backed reputation with sponsors and CROs. Sites that invest in data infrastructure, staff retention, and proactive relationship-building consistently outperform sites relying on reactive RFP responses alone.

If you're building a research site network, evaluating feasibility strategy, or looking to strengthen sponsor relationships, it's worth comparing notes on what's actually driving allocation decisions right now.

Want to discuss your site's feasibility positioning or explore a partnership opportunity? Book a quick chat with Kevin here.

The link has been copied!